... twitching was originally thought to be myokymia (see Clinical Description ); however, more recently EMG studies of affected individuals have revealed that these twitches are not myokymia. DYT- ADCY5 may be an appropriate designation because dystonia is often a prominent feature [ Marras ...

... the European Medicines Agency (EMA) granted TRIAC orphan designation for the treatment of AHDS (EMA/695502/2017). To follow this first clinical study, an international Phase II trial (NCT02396459) to investigate ...

... designation pM0 is not valid; any M0 is clinical. 6. If a patient presents ... imaging studies reveal the presence of distant metastases, provided the ...

... often postoperative as seen in a follow-up study of preoperative versus PORT ... the designation, neoadjuvant, to distinguish it from standard adjuvant therapy, ...

... the following: Radiation ... Risk factors considered in other studies include the number of involved nodal regions, the ...

... be considered interventional in European countries. Because the ... clinical trial submission and compliance with clinical trial regulations), ...

... for clinical use has recently achieved Orphan Drug designation by European Medicines Agency ... 2001 ]. Studies on other complement-regulatory genes would help to ...

... Hidvegi et al 2010 ]. Carbamazepine received orphan drug designation by the ... clinical studies for a wide range of diseases and conditions. ...

... inclusion/exclusion criteria, vital signs), and a core designation (highly ... and postmarketing studies, but it is nonetheless an excellent step in ...